Navigation Links
Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Date:9/4/2007

evidence for the drug's activity as well as help inform dose selection for future studies."

ISIS 325568 Targets the Glucagon Receptor (GCGR)

Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose. In type 2 diabetes, unopposed action of glucagon can lead to increased blood glucose levels. Reducing the expression of liver GCGR using antisense inhibitors, and thereby reducing excessive liver glucose production, is expected to lower blood glucose levels and help control type 2 diabetes. In preclinical studies, antisense inhibitors of GCGR led to improved glucose control and reduced levels of blood triglycerides without producing hypoglycemia. In addition, treatment with ISIS 325568 led to an increase in circulating glucagon-like peptide, or GLP-1, which is a hormone that helps to preserve pancreatic function, thereby enhancing insulin secretion.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis' discovery and development of drugs for diabetes and metabolic diseases, and the potential of the antise
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Malvern initiates European user group meetings for chemical imaging
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 The Physician-Patient Alliance for ... July 28, 2015, "Surviving Your Hospital Stay: Physician-Patient ... Patient Safety." A sentence was omitted ... "PPAHS is a member of the National ... more information on the National Coalition to Promote ...
(Date:7/31/2015)... LONDON , July 31, 2015 ... to decades of experience, the domestic pharmaceutical industry is ... today manufacture products to high international standards. ... well known is in sub-Saharan Africa: Morocco has quietly ... after South Africa . Indeed, Moroccan ...
(Date:7/31/2015)... , July 31, 2015  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, asthma ... of Yujiro S. Hata to its board ... in business and corporate development is a tremendous asset ... president and chief executive officer of Xencor. "Xencor faces ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... 16 Berlin Heart Inc. today announced,its EXCOR(R) Pediatric ... ongoing IDE clinical trial in the United,States of America. ... the Investigational Plan for the IDE study of the ... approval for the prospective,IDE study to begin initially at ...
... Australia, Oct. 16 Cytopia Limited (ASX:,CYT) will ... two important,scientific meetings this month., Dr Emmanuelle ... a,lecture entitled Targeted JAK2 Inhibitors for Myeloproliferative Disorders,at ... Australia and New,Zealand, in Perth, Australia, on 21 ...
Cached Medicine Technology:Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 2Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 3Cytopia Scientific Presentations on JAK2 Inhibitor Program 2
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of ... Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto ... in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, ...
(Date:7/31/2015)... ... ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and black ... Exilis non-surgical fat reduction in New York. Due to its unparalleled level of ... Many patients travel to New York to get their non-surgical skin tightening and ...
(Date:7/31/2015)... ... 2015 , ... The 2nd annual Ride to Fight On will start and ... 2015. The Ride to Fight On is a cycling fundraiser that benefits the West ... Clinic and The University of Tennessee Health Science Center. A health and wellness festival ...
(Date:7/31/2015)... ... 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, ... Center. The medical community, social workers, law enforcement, and government officials are all ... the effort to better understand and combat sex trafficking. Lead by sex trafficking ...
(Date:7/31/2015)... , ... July 31, 2015 , ... M3 USA MDLinx.com, ... to launch three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology ... Exam Prep from MDLinx makes preparing for the exam easy and painless. MDLinx ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... cholesterol lowering drugs known as statins may help prevent future ... The study is published in the August 2, 2011, print ... American Academy of Neurology. "Because the cause of ... drugs are often not used to prevent further strokes or ...
... , MONDAY, Aug. 1 (HealthDay News) -- Teens are ... in or go to school in neighborhoods with many fast ... study finds. Researchers compared 2007 data on junk food ... of junk food outlets, such as fast food restaurants, convenience ...
... By Amanda Gardner HealthDay Reporter , MONDAY, Aug. ... who have been prescribed a controlled medication such as Oxycontin ... are misusing the drugs, a new study has found. ... abuse other substances and to start giving or selling drugs ...
... , Prostate cancer is the number two killer of American men, ... affects more than 2 million American men, and in 2010 there ... kills, but even for those who survive it, the world is ... and depression are common after-effects of prostate cancer, and until now ...
... By Serena Gordon HealthDay Reporter , MONDAY, Aug. ... of the omega 3 fatty acid DHA during pregnancy, their ... indicates. At 1 month and 3 months of age, ... in the womb experienced cold symptoms, compared to about 45 ...
... of Technology (MIT) have developed a new imaging system ... changes in the esophagus or colon. The new system, ... Biomedical Optics Express , is based on an ... a way to see below the surface with 3-D, ...
Cached Medicine News:Health News:Cholesterol-lowering drugs may help prevent recurrent strokes in younger people 2Health News:With Junk Food Stores Nearby, Teens May Eat More of It 2Health News:When Teens Abuse Prescriptions, Addiction Often Follows 2Health News:When Teens Abuse Prescriptions, Addiction Often Follows 3Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 2Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 3Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 2Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 3Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 4
Ernest nucleus cracker extra delicate cross-action serrated paddle shaped jaws for cracking the nucleus through a 2.5 mm incision....
Epilation forceps straight ends size 3.5"....
Removal Forceps, very fine pointed tips, with textured jaws, ideal for grasping wet sutures....
Forceps, extra delicate, straight....
Medicine Products: